Table 3.
Univariate analysis of potential prognostic variables and survival times of scalp angiosarcoma patients
| Variable | Patients (n) | Overall survival | |
| MST (months) | p-value | ||
| Age (years) | |||
| <75 | 10 | 45.76 | 0.8932 |
| ≥75 | 7 | 23.08 | |
| Gender | |||
| Male | 12 | 33.65 | 0.6291 |
| Female | 5 | 24.52 | |
| PS | |||
| 0 | 15 | 25.59 | 0.0824 |
| 1 | 2 | 36.55 | |
| Tumour size (cm) | |||
| <5 | 2 | 33.65 | 0.329 |
| ≥5 | 15 | 23.45 | |
| LN metastasis | |||
| Yes | 3 | 7.072 | 0.0008 |
| No | 14 | 33.65 | |
| Radiation field | |||
| Extended local | 10 | 25.59 | 0.5571 |
| Whole scalp | 7 | 34.61 | |
| Docetaxel | |||
| Yes | 12 | 33.65 | 0.0477 |
| No | 5 | 22.7 | |
| rIL-2 | |||
| Yes | 6 | 18.65 | 0.015 |
| No | 11 | 33.65 | |
| Surgery | |||
| Yes | 3 | 14.61 | 0.0106 |
| No | 13 | 33.65 | |
CTV, clinical target volume; LN, lymph node; MST, median survival time; PS, performance status; rIL-2, recombinant Interleukin-2.